Enliven Therapeutics Reports Promising 44% MMR Rate at 24 Weeks in Phase 1 CML Trial for ELVN-001

Reported cumulative MMR rate of 44% by 24 weeks, with stable or deepening responses between weeks 12 and 24, continuing to surpass prior Phase 1 trials o...

September 30, 2024 | Monday | News
Telesis Bio and Beckman Coulter Life Sciences Partner to Create Scalable Biofoundries for Rapid, High-Fidelity DNA Synthesis

A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient a...

September 26, 2024 | Thursday | News
QIAGEN Launches PAXgene Urine Liquid Biopsy Set, Advancing Non-Invasive cfDNA Collection and Stabilization

PAXgene Urine Liquid Biopsy Set with collection cup and a nucleic acid stabilizing tube enables non-invasive sample collection and direct cell-free DNA sta...

September 26, 2024 | Thursday | News
Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Lupus Nephritis, Demonstrating Superiority Over Standard Therapy Alone

Roche announced positive topline results from the Phase III REGENCY study, which evaluated Gazyva®/Gazyvaro® (obinutuzumab) in people with active...

September 26, 2024 | Thursday | News
Dräger Honored with 2024 AARC Zenith Award for Excellence in Respiratory Care Support

Award criteria include quality of equipment, service and customer support The American Association for Respiratory Care (AARC) selected Dräger for ...

September 25, 2024 | Wednesday | News
Metabolomics Diagnostics Develops PrePsia, an Innovative Test to Predict Preeclampsia Risk in Early Pregnancy

-Metabolomics Diagnostics, a deep-tech machine learning diagnostic platform developer, has developed an innovative test, PrePsia, to accurately predict t...

September 25, 2024 | Wednesday | News
Roche Launches cobas® Respiratory flex Test, Powered by Innovative TAGS Technology

New TAGS (Temperature-Activated Generation of Signal) technology enables up to 15 targets to be detected simultaneously in a single patient sample on t...

September 24, 2024 | Tuesday | News
Novo Nordisk’s Wegovy® Receives Positive Opinion from EMA for Label Update Reflecting Reduced Heart Failure Symptoms

Novo Nordisk announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opin...

September 20, 2024 | Friday | News
Astellas Launches DIGITIVA™, a New Digital Health Solution for Heart Failure Management

New digital health solution for heart failure management puts patients at the center of their care by providing ability for at-home disease monitoring -...

September 19, 2024 | Thursday | News
Novartis Announces FDA Approval of Kisqali® for Expanded Use in Early Breast Cancer, Doubling Eligible Patient Population

– Novartis announced that the U.S. Food and Drug Administration (FDA) has approved Kisqali® (ribociclib) in combination with an aromata...

September 18, 2024 | Wednesday | News
Valneva Seeks to Expand IXCHIQ® Chikungunya Vaccine Use to Adolescents in Europe and Canada

Valneva SE , a specialty vaccine company, announced the submission of label extension applications to the European Medicines Agency (EMA) and Hea...

September 18, 2024 | Wednesday | News
T2 Biosystems Gains FDA Clearance for Pediatric Use of T2Candida® Panel

T2 Biosystems, Inc. (NASDAQ:TTOO) (the “Company”), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance gene...

September 17, 2024 | Tuesday | News
FDA Grants Seven Years of Market Exclusivity to YORVIPATH for Treating Hypoparathyroidism in Adults

U.S. FDA Orphan Drug exclusivity provides seven years of market exclusivity for YORVIPATH in the United States for the treatment of hypoparathyroidism in...

September 12, 2024 | Thursday | News
Vasa Therapeutics' Novel Heart Failure Treatment VS-041 Reaches Key Clinical Advancement with First Dosing in Human Trials

VS-041, a novel and potentially life-saving  treatment for heart failure, developed by Vasa Therapeutics, a San Diego-based biotechnology  comp...

September 11, 2024 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close